A systematic literature review of the human skin microbiome as biomarker for dermatological drug development

Kolk, Tessa Niemeyer–van der; Wall, Hein E. C. van der; Balmforth, C.; Doorn, Martijn van; Rißmann, Robert

doi:10.1111/bcp.13662

Cited by 28 publications

(30 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data determined that Corynebacterium was the most dominant genus within the device and contralateral intact thigh skin and varied little over time. This is not surprising, as Corynebacterium has been reported to be the most abundant genus in the anterior thigh region in the human skin microbiome . From the human microbiome project, it is now understood that microbial ecologies or compositions are specific to physiological characteristics of the sampled skin regions (i.e., moist, dry or oily regions).…”

Section: Discussionmentioning

confidence: 98%

Analysis of the Stomal Microbiota of a Percutaneous Osseointegrated Prosthesis: A Longitudinal Prospective Cohort Study

Beck

Grogan

Bennett

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

Percutaneous osseointegrated (OI) prostheses (POPs) are used to skeletally attach artificial limbs in amputees. While any permanent percutaneous interface is at risk of becoming infected by the resident microbiota colonizing the stoma, most of these patients remain infection-free. Avoidance of infection likely depends upon a mechanically and/or biologically stable skin-to-implant interface. The ultimate question remains, "why do some stomata become infected while others do not?" The answer might be found in the dynamic bacterial communities of the patient and within the stomal site itself. This study is an appendix to the first Food and Drug Administration approved prospective early feasibility study of OI prosthetic docking, in which, 10 transfemoral amputees were implanted with a unique POP device. In this analytical, longitudinal cohort study, each patient's skin and stomal microbiota were analyzed from the initial surgery to 1 year following the second-stage surgery. During each follow-up visit, three swab samples-stomal, device thigh skin and contralateral thigh skin-were obtained. DNA was extracted, and bacterial 16S ribosomal RNA (rRNA) genes were amplified and sequenced to profile microbial communities. The stomal microbiota were distinct from the microbiota on the adjacent thigh skin and the skin of the contralateral thigh, with a significantly increased abundance of Staphylococcus aureus within the stoma. Early on stomal microbiota were characterized by high diversity and high relative abundance of obligate anaerobes. Over time, the stomal microbiota shifted and stabilized in communities of lower diversity dominated by Streptococcus, Corynebacterium, and/or Staphylococcus spp.

show abstract

Section: Discussionmentioning

confidence: 98%

Analysis of the Stomal Microbiota of a Percutaneous Osseointegrated Prosthesis: A Longitudinal Prospective Cohort Study

Beck

Grogan

Bennett

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

show abstract

“…In particular, S aureus colonization was significantly higher among SD patients than healthy controls . Furthermore, multiple studies support a relationship between the skin microbiota, disease severity and clinical response to treatment in AD and acne vulgaris patient . Similarly, deviation from the normal skin microbiome may trigger inflammatory response in SD.…”

Section: Other Predisposing and Causative Factorsmentioning

confidence: 92%

Seborrheic dermatitis—Looking beyond Malassezia

Wikramanayake

Borda

Miteva

et al. 2019

Experimental Dermatology

101

View full text Add to dashboard Cite

Seborrhoeic Dermatitis (SD) is a very common chronic and/or relapsing inflammatory skin disorder whose pathophysiology remains poorly understood. Yeast of the genus Malassezia has long been regarded as a main predisposing factor, even though causal relationship has not been firmly established. Additional predisposing factors have been described, including sebaceous activity, host immunity (especially HIV infection), epidermal barrier integrity, skin microbiota, endocrine and neurologic factors, and environmental influences. Genetic studies in humans and mouse models—with particularly interesting insights from examining the Mpzl3 knockout mice and their SD‐like skin phenotype, and patients carrying a ZNF750 mutation—highlight defects in host immunity, epidermal barrier and sebaceous activity. After synthesizing key evidence from the literature, we propose that intrinsic host factors, such as changes in the amount or composition of sebum and/or defective epidermal barrier, rather than Malassezia, may form the basis of SD pathobiology. We argue that these intrinsic changes provide favourable conditions for the commensal Malassezia to over‐colonize and elicit host inflammatory response. Aberrant host immune activity or failure to clear skin microbes may bypass the initial epidermal or sebaceous abnormalities. We delineate specific future clinical investigations, complemented by studies in suitable SD animal models, that dissect the roles of different epidermal compartments and immune components as well as their crosstalk and interactions with the skin microbiota during the process of SD. This research perspective beyond the conventional Malassezia‐centric view of SD pathogenesis is expected to enable the development of better therapeutic interventions for the management of recurrent SD.

show abstract

“…Calcineurin inhibitor 2 (17) 7 (58) 2 (17) 11 (31) BSA, body surface area; oSCORAD, objective SCORing Atopic Dematitis; SD, standard deviation.…”

Section: Treatment Compliance and Exposurementioning

confidence: 99%

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

Kolk

Wall

Hogendoorn

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis. In this randomized, double‐blind, placebo‐controlled, phase II trial we explored the efficacy, pharmacodynamics, and safety of topical omiganan once daily in 36 patients with mild to moderate atomic dermatitis. Patients were randomized to apply topical omiganan 1%, omiganan 2.5%, or vehicle gel to one target lesion once daily for 28 consecutive days. Small but significant improvements in local objective SCORing Atopic Dematitis index and morning itch were observed in the omiganan 2.5% group compared with the vehicle gel group (−18.5%; 95% confidence interval, −32.9 to −1.0; P = 0.04; and −8.2; 95% confidence interval, −16.3 to −0.2; P = 0.05, respectively). A shift from lesional to nonlesional skin microbiota was observed in both omiganan treatment groups, in contrast to the vehicle group. Thus, treatment with topical omiganan improved dysbiosis in patients with mild to moderate atopic dermatitis, and small but statistically significant improvements in clinical scores were detected. Our findings warrant further exploration in future clinical trials.

show abstract

A systematic literature review of the human skin microbiome as biomarker for dermatological drug development

Cited by 28 publications

References 91 publications

Analysis of the Stomal Microbiota of a Percutaneous Osseointegrated Prosthesis: A Longitudinal Prospective Cohort Study

Analysis of the Stomal Microbiota of a Percutaneous Osseointegrated Prosthesis: A Longitudinal Prospective Cohort Study

Seborrheic dermatitis—Looking beyond Malassezia

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

Contact Info

Product

Resources

About